Insider · CIK 0001886431

Fitzgerald Kevin Joseph

Reports to the SEC for 2 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001886431

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-04-07	OVIDOvid Therapeutics Inc.A Award	Director	AAward	+17.6K sh	$2.56	+$45K	17,578
2026-03-05	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−148 sh	$324.60	−$48K	20,722
2026-03-05	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−233 sh	$323.25	−$75.3K	20,870
2026-03-05	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−153 sh	$326.24	−$49.9K	20,569
2026-03-05	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−124 sh	$321.81	−$39.9K	21,103
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−79 sh	$321.82	−$25.4K	21,665
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−96 sh	$323.01	−$31K	21,569
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−29 sh	$319.03	−$9,251.87	21,831
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−59 sh	$320.81	−$18.9K	21,744
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−57 sh	$325.67	−$18.6K	21,227
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−28 sh	$320.01	−$8,960.28	21,803
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−75 sh	$324.88	−$24.4K	21,284
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−210 sh	$323.84	−$68K	21,359
2026-03-03	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−359 sh	$321.58	−$115K	21,860
2026-03-03	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−282 sh	$318.62	−$89.9K	22,941
2026-03-03	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−289 sh	$316.55	−$91.5K	23,223
2026-03-03	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−722 sh	$320.51	−$231K	22,219
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.A Award	CSO & EVP, Head of Research	AAward	+3,688 sh	—	—	25,110
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−258 sh	$325.63	−$84K	24,715
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−47 sh	$323.62	−$15.2K	25,063
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−170 sh	$329.71	−$56.1K	23,724
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−81 sh	$330.85	−$26.8K	23,643
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−94 sh	$331.93	−$31.2K	23,549
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−100 sh	$328.71	−$32.9K	23,894
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−392 sh	$326.81	−$128K	24,323
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−37 sh	$332.64	−$12.3K	23,512
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−329 sh	$327.67	−$108K	23,994
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−90 sh	$324.65	−$29.2K	24,973
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	CSO & EVP, Head of Research	AAward	+8,105 sh	—	—	8,105
2026-02-26	OVIDOvid Therapeutics Inc. · Employee Stock Option (Right to Buy)A Award	Director	AAward	+65K sh	—	—	65,000
2026-02-23	ALNYALNYLAM PHARMACEUTICALS, INC.A Award	CSO & EVP, Head of Research	AAward	+158 sh	—	—	21,422
2026-02-17	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−2,041 sh	$331.96	−$678K	21,264
2026-02-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−1,959 sh	$310.08	−$607K	23,305
2026-02-12	ALNYALNYLAM PHARMACEUTICALS, INC.A Award	CSO & EVP, Head of Research	AAward	+4,000 sh	—	—	25,264
2026-01-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−280 sh	$372.93	−$104K	21,386
2026-01-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−122 sh	$374.33	−$45.7K	21,264
2026-01-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−644 sh	$370.00	−$238K	22,151
2026-01-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−485 sh	$371.24	−$180K	21,666
2026-01-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−562 sh	$368.76	−$207K	22,795
2026-01-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−197 sh	$367.52	−$72.4K	23,357
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−14 sh	$374.44	−$5,242.16	23,588
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−19 sh	$375.65	−$7,137.35	23,569
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−19 sh	$370.87	−$7,046.53	23,604
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−123 sh	$358.18	−$44.1K	24,723
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−2 sh	$372.46	−$744.92	23,602
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−85 sh	$359.14	−$30.5K	24,638
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−39 sh	$353.95	−$13.8K	25,025
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−40 sh	$369.48	−$14.8K	23,623
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−42 sh	$355.16	−$14.9K	24,983
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	CSO & EVP, Head of Research	SSale	−199 sh	$364.83	−$72.6K	24,066

Recent filings

Accepted (ET)
Apr 94
Fitzgerald Kevin Joseph0001886431-26-000004
SEC(opens sec.gov)
Mar 64
Fitzgerald Kevin Joseph0001735276-26-000059
SEC(opens sec.gov)
Mar 44
Fitzgerald Kevin Joseph0001735276-26-000051
SEC(opens sec.gov)

Companies

Address

C/O OVID THERAPEUTICS INC. 441 NINTH AVENUE

NEW YORK, NY, 10001